Related Experiment Videos
A fluorometric assay for beta-phenylethylamine in human urine
Summary
A new method accurately measures beta-phenylethylamine (PEA) in urine. Schizophrenic patients excrete less PEA than healthy individuals, suggesting a link between PEA levels and schizophrenia.
Area of Science:
- Biochemistry
- Clinical Chemistry
- Neuroscience
Background:
- Beta-phenylethylamine (PEA) is a trace amine with neuromodulatory functions.
- Altered PEA levels have been implicated in various neurological and psychiatric conditions, including schizophrenia.
- Accurate quantification of PEA in biological samples is crucial for understanding its role in health and disease.
Purpose of the Study:
- To develop and validate a sensitive and specific fluorometric method for determining free beta-phenylethylamine (PEA) in human urine.
- To compare urinary PEA excretion levels between normal subjects and individuals with chronic schizophrenia.
- To investigate the diurnal excretion pattern of free PEA in normal individuals.
Main Methods:
- Development of a fluorometric assay for PEA determination.
- Separation of PEA from interfering compounds (phenylalanine, 5-hydroxytryptamine) using n-heptane extraction.
- Quantification of PEA using the ninhydrin reaction in the presence of L-leucyl-L-alanine.
Main Results:
- The described method provides sensitive and specific measurement of urinary PEA.
- Normal subjects excreted an average of 15.9 +/- 6.4 microg/day of free PEA.
- Chronic schizophrenics excreted significantly lower levels of free PEA, averaging 9.3 +/- 2.7 microg/day.
- In healthy individuals, peak urinary PEA excretion occurred between 4:00 PM and 12:00 AM.
Conclusions:
- The developed method is suitable for measuring free PEA in human urine.
- Reduced urinary PEA excretion may be associated with chronic schizophrenia.
- Further research is warranted to elucidate the role of PEA in the pathophysiology of schizophrenia and other psychiatric disorders.